Schering Plough has completed patient enrolment for a piece of phase III research in to its boceprevir therapy, according to the company.
Named the boceprevir HCV Sprint-2 study, it will see treatment-naive people receiving the organisation's lead investigational oral hepatitis C therapy.
Thomas Koestler, executive vice-president and president of Schering Plough's Research Institute, said the business believed the drug has the potential to be a "first-in-class and best-in-class" protease inhibitor for the disease.
He added: "We are very encouraged by the boceprevir study results reported to date and look forward to the completion of these registration studies."
Expected to be completed in mid-2010, the trial follows a phase II study, in which 595 patients with hepatitis C were treated with a 48-week boceprevir regimen.
The therapy was found to achieve a 75 per cent sustained viral response 24 weeks after the end of treatment.
In November, Schering Plough announced its Preladenant had met the primary endpoint in trials.
The study of the drug analysed the safety and efficacy of the drug in 253 patients.